B

한국비엔씨

256840KOSDAQ

61.3 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40
News Sentiment21.3 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 3.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea BNC is a biotech company established in 2007, specializing in the research, development, and distribution of medical devices, aesthetic equipment, pharmaceuticals, and cosmeceutical products based on hyaluronic acid and collagen. Its main revenue streams include aesthetic medical products (58.2%) and reagents/test equipment (25.2%), with growth driven by global partnerships in the medical and bio sectors.

Number of Employees

295people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
90.06Industry Average 15.000.0Point

6.0x industry avg (risky)

PBR
0.77Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
0.86Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
9.67Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.8% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 6.6% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 2,695Won52-week high 6,05052-week low 2,170
1-month return4.0Point

1m +3.65% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-14